|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Trial implications for diabetes management and the impact of the new ADA/EASD consensus statement treatment algorithm were highlighted for diabetologists, cardiologists, endocrinologists, nephrologists and general practitioners.
|
30857522 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
With the implementation of ADA 2011 (International Association of the Diabetes and Pregnancy Study Groups) guidelines, there are fewer adverse perinatal outcomes and cases of type 2 diabetes mellitus in the long term, but the medical costs increased significantly, and the cost-effectiveness of diagnostic criteria in China is still yet to be confirmed.
|
30663279 |
2019 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Diabetes mellitus and hypertension increased the serum ADA activity in CAD patients.
|
31839921 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Participants completed six tools (the Finnish Diabetes Risk Score [FINDRISC], the Canadian Diabetes Risk Score [CANRISK], the Indian Diabetes Risk Score [IDRS], the American Diabetes Association [ADA] risk score, an Indonesian undiagnosed diabetes mellitus [UDDM] scoring system, and a Filipino tool).
|
31455247 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
In 2010, the ADA made the recommendation to include hemoglobin A1c (HbA1c) as a diagnostic test for diabetes, in addition to the oral glucose tolerance test or fasting plasma glucose.
|
29868987 |
2018 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
The overall prevalence of undiagnosed diabetes was 9.8% (1059/10794) according to ADA criteria.
|
30115607 |
2018 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
According to the ADA criteria of HbA1c cut-off point (5.7%), 3,517 subjects with NGT screened from a total of 7,855 middle-aged and elderly Chinese without known diabetes were divided into two groups, 1,877 subjects with HbA1c < 5.7% and 1,640 with HbA1c ≥ 5.7% (i.e. iHH).
|
28904260 |
2018 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Patients aged 45-75 years within 2 years of first fulfilling the ADA criteria for diabetes will be prospectively enrolled in this study.
|
29192743 |
2018 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Four researchers manually reviewed all records and classified patients according to their diabetic status (diabetic: diabetes registered as a health problem or fulfilling the ADA criteria; non-diabetic: not fulfilling the ADA criteria and having at least one fasting glycemia below 126 mg/dL; inconclusive: no data regarding their diabetic status or only one abnormal value).
|
29054261 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
ADA = American Diabetes Association BG = blood glucose DM = diabetes mellitus GLP-1 = glucagon-like peptide 1 HBA1c = glycated hemoglobin LOS = length of stay NPH = neutral protamine Hagedorn SNF = skilled nursing facility SSI = sliding-scale insulin.
|
28156156 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Serum ADA activities were significantly higher in cases compared with controls (p<0.001) showing significant positive correlation (p<0.05) with FBS, PPBS, HbA1c, and alcoholism; while no correlation was found with age, sex, ethnicity, BMI, waist-hip ratio, dietary habits, smoking, and duration of diabetes.
|
28321313 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
ADA = American Diabetes Association CRP = C-reactive protein DD = definite diabetes FPG = fasting plasma glucose HbA1c = glycosylated hemoglobin MENA = Middle-East North Africa ND = no diabetes PD = probable diabetes RD = at risk of diabetes T2D = type 2 diabetes mellitus TSH = thyroid-stimulating hormone.
|
28683240 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
ACEI = angiotensin-converting enzyme inhibitors; ADA = American Diabetes Association; ARB = angiotensin-receptor blocker; CAD = coronary artery disease; Cr = creatinine; CVD = cardiovascular disease; DM = diabetes mellitus; HF = heart failure; HT = hypertension; JNC = Joint National Committee; KAUH = King Abdullah University Hospital; LV = left ventricular; PAD = peripheral artery disease; RAAS = renin-angiotensin-aldosterone system; TIA = transient ischemic attack.
|
28816537 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
We compared prediabetes definitions based on fasting glucose concentration (American Diabetes Association [ADA] fasting glucose concentration cutoff 5·6-6·9 mmol/L and WHO fasting glucose concentration cutoff 6·1-6·9 mmol/L), HbA<sub>1c</sub> (ADA HbA<sub>1c</sub> cutoff 5·7-6·4% [39-46 mmol/mol] and International Expert Committee [IEC] HbA<sub>1c</sub> cutoff 6·0-6·4% [42-46 mmol/mol]), and 2 h glucose concentration (ADA and WHO 2 h glucose concentration cutoff 7·8-11·0 mmol/L).
|
27863979 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Patients with diabetes: ADA*01;*01 (142/159, 89.3%), ADA*01;*02 (16/159, 10.1%) and ADA*02;*02 (1/159, 0.6%); control group: ADA*01;*01 (146/160, 91.3%), ADA*01;*02 (12/160, 7.5%) and ADA*02;*02 (2/160, 1.3%); patients at risk of cardiovascular disease: ADA*01;*01 (71/78, 91.0%), ADA*01;*02 (7/78, 9.0%) and ADA*02;*02 (0/78, 0.0%).
|
24836059 |
2014 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Revision of the ADA-classification of diabetes mellitus type 2 (DMT2): the importance of maturity onset diabetes (MOD), and senile diabetes (DS).
|
20800300 |
2011 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
The association of ACP1 and ADA1 with CAD depends on sex and diabetes.
|
20581655 |
2010 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Ketosis-prone atypical diabetes that has been classified by ADA as idiopathic Type 1 diabetes or Type 1b is the most common atypical form.
|
11938022 |
2002 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Digging the genome for diabetes mellitus: the 2nd ADA Research Symposium on the Genetics of Diabetes, San Jose, CA, USA, 17-19 October 1999.
|
11228869 |
2001 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To assess, by a house to house study, the prevalence of diabetes, impaired glucose tolerance (IGT) and their associated risk factors in Benghazi, Libya using 75 gram oral glucose tolerance test (OGTT) and ADA 1997 and WHO 1998 diagnostic criteria.
|
11852372 |
2001 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
These patients (2 out of 141) that cannot be classified as Type 1a diabetic patients lack clinical characteristics of Type 1b diabetes and have to be reconsidered for a more appropriate ADA classification.
|
10707033 |
2000 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
According to ADA criteria, 588 (74.6%) women were normal, 46 (5.8%) had impaired fasting glucose, 82 (10.4%) had impaired glucose tolerance, 29 (3.7%) had both impaired fasting glucose and impaired glucose tolerance, and 43 (5.4%) had diabetes.
|
10388966 |
1999 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Because HLA typing (DQbeta-57 Asp/Asp and DQalpha-52 Ser/Ser) showed no alleles usually associated with IDDM, and ICA were repeatedly negative even after treatment with PEG-ADA and gene transplant, hypotheses on the pathogenesis of diabetes mellitus in this patient are discussed.
|
9364370 |
1997 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A further single large pedigree with MODY has shown linkage to a marker for the adenosine deaminase gene (ADA, chromosome 20q), although the diabetes susceptibility gene at this locus has not been identified.
|
7705022 |
1994 |